RT journal article
T1 Erythropoietin Improves Atrophy, Bleeding and Cognition in the Newborn Intraventricular Hemorrhage
A1 Hierro Bujalance, Carmen
A1 Infante-Garcia, Carmen
A1 Sanchez Sotano, Daniel
A1 Marco Delgado, Ángel José del
A1 Casado Revuelta, Ana
A1 Mengual Gonzalez, Carmen Maria
A1 Lucena Porras, Carmen
A1 Bernal Martin, Marcos
A1 Benavente Fernández, Isabel
A1 Lubián López, Simón Pedro
A1 García Alloza, Mónica
A2 BiomedicinaBiotecnología y Salud Pública
K1 brain atrophy
K1 neuronal loss
K1 erythropoietin
K1 gelsolin
K1 germinal matrix-intraventricular hemorrhage
K1 preterm infant
AB The germinal matrix-intraventricular hemorrhage (GM-IVH) is one of the most devastating complications of prematurity. The short- and long-term neurodevelopmental consequences after severe GM-IVH are a major concern for neonatologists. These kids are at high risk of psychomotor alterations and cerebral palsy; however, therapeutic approaches are limited. Erythropoietin (EPO) has been previously used to treat several central nervous system complications due to its role in angiogenesis, neurogenesis and as growth factor. In addition, EPO is regularly used to reduce the number of transfusions in the preterm infant. Moreover, EPO crosses the blood-brain barrier and EPO receptors are expressed in the human brain throughout development. To analyze the role of EPO in the GM-IVH, we have administered intraventricular collagenase (Col) to P7 mice, as a model of GM-IVH of the preterm infant. After EPO treatment, we have characterized our animals in the short (14 days) and the long (70 days) term. In our hands, EPO treatment significantly limited brain atrophy and ventricle enlargement. EPO also restored neuronal density and ameliorated dendritic spine loss. Likewise, inflammation and small vessel bleeding were also reduced, resulting in the preservation of learning and memory abilities. Moreover, plasma gelsolin levels, as a feasible peripheral marker of GM-IVH-induced damage, recovered after EPO treatment. Altogether, our data support the positive effect of EPO treatment in our preclinical model of GM-IVH, both in the short and the long term.
PB FRONTIERS MEDIA SA
SN 2296-634X
YR 2020
FD 2020-09
LK http://hdl.handle.net/10498/23940
UL http://hdl.handle.net/10498/23940
LA eng
DS Repositorio Institucional de la Universidad de Cádiz
RD 10-nov-2026